Recce (ASX:RCE) share price edges higher after patent approval

The pharmaceutical company is making progress of late. Here are the details

| More on:
Group of doctors celebrate by pumping fists in the air

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Recce Pharmaceuticals Ltd (ASX: RCE) share price ended the day higher after the company secured a patent in the United States.

At the closing bell, the pharmaceutical company's shares finished the day up 3.27% to $1.10.

Let's take a closer look at what Recce announced to the ASX this morning.

Recce furthers patent protection

According to its release, the United States Patent and Trademark Office has granted Patent Family 3 to Recce anti-infectives.

Titled "Anti-Virus Agent and Method for Treatment of Viral Infections", the patent furthers the company's marketing and manufacturing property until February 2037.

The approved claims relate to its flagship drug, Recce 327, and anti-viral formulation, Recce 529. They are as follows:

  • Composition/method of manufacture of Recce anti-infectives;
  • Use of Recce 327 or Recce 529 for the treatment of viruses having a lipid envelope or coat, examples being SARS-CoV-2 and Corona viruses, Influenza viruses, HIV, Hepatitis, Ross River and Herpes viruses; and
  • Administration of Recce 327 or Recce 529 by oral, injection, inhalation and transdermal dose applications.

Recce's lead drug candidate (Recce 327) is being developed to treat blood infections and sepsis.

Investors appeared buoyed by this latest development, sending the Recce share price higher on Thursday.

According to World Atlas, the US is the largest pharmaceutical market in the world, valued at $33.97 billion. The country's stringent processes in developing and manufacturing drugs has led to some of the best-selling products across the globe.

Just this week, China also granted Recce Patent Family 3 to its anti-infectives. This leaves Australia as the only remaining nation yet to approve the patent. China, Japan, Europe and now the United States have all authorised Recce's Family 3 patent.

Recce CEO James Graham said:

Recce's intellectual property portfolio continues to grow in-line with our business strategy and the unprecedented global infectious disease crisis before us. We are thrilled to see that our anti-viral patent granted in the USA, the largest pharmaceutical market in the world; with yet further market-monopolies reinforcing the unique opportunities among a significant range of both bacterial and viral pathogens.

Recce share price summary

Despite today's rise, Recce shares have had a disappointing 12 months, falling more than 15%. However, year-to-date, the company's share price is slightly up by 5%.

Recce has a market capitalisation of roughly $192 million, ranking as the 722nd largest company on the ASX.

Should you invest $1,000 in Appen Limited right now?

Before you buy Appen Limited shares, consider this:

Motley Fool investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now... and Appen Limited wasn't one of them.

The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

And right now, Scott thinks there are 5 stocks that may be better buys...

See The 5 Stocks *Returns as of 30 April 2025

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Share Market News

Person pretends to types on laptop drawn in sand.
Share Gainers

Here are the top 10 ASX 200 shares today

ASX investors had a rough start to the week today.

Read more »

Happy man working on his laptop.
Broker Notes

Leading brokers name 3 ASX shares to buy today

Here's why brokers believe that now could be the time to snap up these shares.

Read more »

Two funeral workers with a laptop surrounded by cofins.
Broker Notes

Macquarie just forecast this ASX 300 dividend share could surge 37%. Here's why

Atop its passive income payouts, Macquarie expects this ASX dividend stock could leap 37% in a year.

Read more »

A person in a gorilla suit leaps really high holding a banana, nearly doing the splits.
Share Gainers

Up 1,238% in a year, why is this ASX gold stock surging again on Monday?

The ASX gold stock is now well into ten-bagger range and still rising fast today.

Read more »

A happy investor sits at his desk in front of his laptop and does the mexican wave with his arms to celebrate the returns from his ASX dividend shares
Share Gainers

Why EOS, Gorilla Gold, Lendlease, and OFX shares are charging higher today

These shares are starting the week on a positive note. But why?

Read more »

A young male investor wearing a white business shirt screams in frustration with his hands grasping his hair after ASX 200 shares fell rapidly today and appear to be heading into a stock market crash
Share Fallers

Why Appen, DroneShield, Gentrack, and New Hope shares are dropping today

These shares are starting the week in the red. But why?

Read more »

An unhappy man in a suit sits at his desk with his arms crossed staring at his laptop screen as the PointsBet share price falls
Materials Shares

Does Macquarie rate James Hardie shares a buy, hold or sell?

The company is set to report FY25 earnings this week.

Read more »

A man looking at his laptop and thinking.
Industrials Shares

Which ASX 200 industrials stock does Macquarie expect to sink 40% over the next 12 months?

Can this name build it's way out of such negative sentiment?

Read more »